Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04085250
Recruitment Status : Not yet recruiting
First Posted : September 11, 2019
Last Update Posted : September 11, 2019
Sponsor:
Information provided by (Responsible Party):
Hui Liu, Sun Yat-sen University

Brief Summary:
The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following neoadjuvant chemotherapy plus nivolumab and definitive concurrent chemoradiation therapy

Condition or disease Intervention/treatment Phase
Stage III Non-small-cell Lung Cancer Other: Neoadjuvant therapy Other: Chemotherapy concurrent with radiotherapy Radiation: Radiotherapy Drug: Nivolumab Other: Observation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 264 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Estimated Study Start Date : October 8, 2019
Estimated Primary Completion Date : October 7, 2023
Estimated Study Completion Date : October 7, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab Consolidation
Patients in experimental group will receive Nivolumab consolidation (480 mg) via iv infusion Q4W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
Other: Neoadjuvant therapy
The neoadjuvant therapy before radiotherapy comprised of Docetaxel 75 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.

Other: Chemotherapy concurrent with radiotherapy
Docetaxel 25 mg/m2for 1 hour +Cisplatin 25 mg/m2, once a week (QW), for a total of 4 weeks.

Radiation: Radiotherapy
Simultaneousintegrated boost intensity-modulated radiation therapy(SIB-IMRT) technique was used to deliver a definitive radiation dose

Drug: Nivolumab
Nivolumab consolidation (480 mg) via iv infusion once every 4 weeks (Q4W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q4W schedule for a maximum duration of 12 months.

Active Comparator: Observation
Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
Other: Neoadjuvant therapy
The neoadjuvant therapy before radiotherapy comprised of Docetaxel 75 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.

Other: Chemotherapy concurrent with radiotherapy
Docetaxel 25 mg/m2for 1 hour +Cisplatin 25 mg/m2, once a week (QW), for a total of 4 weeks.

Radiation: Radiotherapy
Simultaneousintegrated boost intensity-modulated radiation therapy(SIB-IMRT) technique was used to deliver a definitive radiation dose

Other: Observation
Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.




Primary Outcome Measures :
  1. Progression-free Survival [ Time Frame: 2 years ]
    To assess the efficacy of Nivolumab consolidation compared with observation in terms of progression-free survival


Secondary Outcome Measures :
  1. Overall Survival(OS) [ Time Frame: 2 years ]
    To assess the efficacy of Nivolumab consolidation compared with observation in terms of Overall survival

  2. Objective Response Rate(ORR) [ Time Frame: 3 weeks ]

    To assess the efficacy of Nivolumab consolidation compared with observation in terms of Objective Response Rate

    -To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of objective response rate after neoadjuvant therapy


  3. Adverse Event [ Time Frame: 2 years ]
    To assess the safety of Nivolumab consolidation compared with observation in terms of adverse event

  4. Symptoms and Health-related Quality of Life [ Time Frame: 2 years ]
    To assess the symptoms and health-related quality of life in patients treated with Nivolumab consolidation compared with observation

  5. Progression-free Survival [ Time Frame: 2 years ]
    To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of progression-free survival for all patients

  6. Overall Survival [ Time Frame: 2 years ]
    To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of overall survival for all patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:

    • Provision of signed, written and dated informed consent prior to any study specific procedures;
    • Male or female aged 18 years or older;
    • Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced, unresectable (Stage III) disease;
    • Without prior chemotherapy, radiotherapy, surgery or immunotherapy;
    • Tumour sample requirements: Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow for analysis;
    • A recent tumour biopsy (taken following completion of the most recent therapy) is an optional requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk;
    • Life expectancy ≥12 weeks;
    • World Health Organization (WHO) Performance Status of 0 or 1;
    • Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 24 hrs before the use of study drug (HCG has a minimum sensitivity of 25 IU/L or equivalent);
    • Women must be non-breastfeeding
    • Women of reproductive age (WOCBP) must agree to comply with the contraceptive method during the study nivolumab treatment and for a period of 5 months following the last administration of the study treatment (i.e., 30 days [ovulation cycle] plus approximately 5 half-lives of the study drug).
    • Men who have sex with WOCBP must agree to comply with the contraceptive method during the study nivolumab treatment and for 7 months after the last administration of the study treatment (i.e. 90 days [sperm renewal cycle] plus approximately 5 half-life of the study drug).
    • Spermless men do not have to comply with contraceptive requirements. WOCBP who continues to be asexual with the opposite sex does not have to comply with contraceptive requirements, but must still undergo the pregnancy tests described in this section.
    • Adequate organ and marrow function as defined below:
  • Forced expiratory volume in 1 second (FEV1) ≥800ml
  • Absolute neutrophil count >1.5 x 109/L (1500 per mm3)
  • Platelets >100 x 109/L (100,000 per mm3)
  • Haemoglobin≥9.0 g/dL (5.59 mmol/L)
  • Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula (Cockcroft and

    -Gault 1976)

  • Serum bilirubin ≤1.5 x upper limit of normal (ULN). ··Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN

Exclusion Criteria:

  • Exclusion criteria for enrolment for neoadjuvant therapy

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  • Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
  • Mixed small cell and non-small cell lung cancer histology;
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
  • Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody;
  • Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of nivolumab;
  • Active or prior documented autoimmune disease within the past 2 years;
  • Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
  • History of primary immunodeficiency;
  • History of organ transplant that requires therapeutic immunosuppression;
  • Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from3 electrocardiograms (ECGs) using Bazett's Correction;
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
  • Known history of tuberculosis;
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within30 days of receiving nivolumab;
  • History of another primary malignancy within 5 years prior to starting nivolumab, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
  • Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control;
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the nivolumab or interpretation of patient safety or study results.

Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy

Patients should not enter the concurrent chemoradiation phase if any of the following exclusion criteria are fulfilled:

  • Patients who develop distant metastasis;
  • Patients who develop locoregional disease progression and the irradiation dose of normal tissue will exceed the limit as defined in Section 7.
  • World Health Organization (WHO) Performance Status of 2-4;
  • Inadequate organ and marrow function as defined below:

    • Forced expiratory volume in 1 second (FEV1) <800ml
    • Absolute neutrophil count <1.5 x 109/L (1500 per mm3)
    • Platelets <100 x 109/L (100,000 per mm3)
    • Haemoglobin<9.0 g/dL (5.59 mmol/L)
    • Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and
  • Gault 1976)

    • Serum bilirubin >1.5 x upper limit of normal (ULN).
    • Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN

Further exclusion criteria for randomization into Nivolumab consolidation or observation group

Patients should not enter the randomization if any of the following exclusion criteria are fulfilled:

  • Patients who have progressed whilst definitive platinum based, concurrent chemoradiation therapy;
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
  • Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization;
  • Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization; Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04085250


Contacts
Layout table for location contacts
Contact: Bo Qiu, MD +86-020-87343031 qiubo@sysucc.org.cn
Contact: Hui Liu, MD +86-020-87343031 liuhui@sysucc.org.cn

Locations
Layout table for location information
China, Guangdong
The First People's Hospital of Foshan Not yet recruiting
Foshan, Guangdong, China, 528000
Contact: Weineng Feng, MD         
Sun yat-sen university cancer center Not yet recruiting
Guangzhou, Guangdong, China, 510000
The first affliated hospital of Guangzhou Medical University Not yet recruiting
Guangzhou, Guangdong, China, 510000
Contact: WenHua Liang, MD         
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Layout table for investigator information
Principal Investigator: Li Zhang, MD Sun Yat-sen University
Principal Investigator: Hui Liu, MD Sun Yat-sen University

Publications:

Layout table for additonal information
Responsible Party: Hui Liu, Prof, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT04085250     History of Changes
Other Study ID Numbers: 2019-FXY-119
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: September 11, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hui Liu, Sun Yat-sen University:
Stage III Non-Small Cell Lung Cancer
Neoadjuvant Chemotherapy plus nivolumab
Chemoradiotherapy
Nivolumab consolidation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents